Cited by 573Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Open access

Kelly, Karen, Chansky, Kari, Gaspar, Laurie E., Albain, Kathy S., Jett, James, Ung, Yee C., Lau, Derick H.M., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.4824

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease. PATIENTS AND METHODS: Untreated patients with stage III NSCLC, a performance score of 0 to 1, and adequate organ function were eligible. All patients received cisplatin 50 mg/m(2) on days 1 and 8 plus etoposide 50 mg/m(2) on days 1 to 5, every 28 days for two cycles with concurrent thoracic radiation (1.8- to 2-Gy fractions per day; total dose, 61 Gy) followed by three cycles of docetaxel 75 mg/m(2). Patients whose disease did not progress were randomly assigned to gefitinib 250 mg/d or placebo until disease progression, intolerable toxicity, or the end of 5 years. The planned sample size was 672 patients to confer power of 0.89 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, log-rank test). Random assignment was stratified by stage, histology, and measurable versus nonmeasurable disease. RESULTS: Enrollment began in July 2001. An unplanned interim analysis conducted in April 2005 rejected the alternative hypothesis of improved survival at the P = .0015 level for 243 randomly assigned patients. The study closed, and preliminary results were reported. Now, with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P = .013). The toxic death rate was 2% with gefitinib compared with 0% for placebo. CONCLUSION: In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.4824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 201–300 of 573

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery
Ahn, H. K., Choi, Y., Han, J. H., Ahn, Y. C., Kim, K., Kim, J., Shim, Y. M., Um, S., Kim, H., Kwon, O. J., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.010 · Cited by 22
Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Redman, M. W., Goldman, B. H., LeBlanc, M. L., Schott, A. F., & Baker, L. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2939 · Cited by 23
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
Sattler, M., Abidoye, O. O., & Salgia, R. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.117 · Cited by 22
Gefitinib in the treatment of advanced non-small-cell lung cancer
Reck, M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.1 · Cited by 22
Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study
Wu, L., Cheng, B., Sun, X., Zhang, Z., Kang, J., Chen, Y., Xu, Q., Yang, S., Yan, Y., Ren, S., et al. (2024) · MedComm · doi:10.1002/mco2.501 · Cited by 22
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
Thatcher, N. J., & Heighway, J. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0292 · Cited by 21
Advances in the Treatment of Stage III Non–Small Cell Lung Cancer
Myall, N. J., & Das, M. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.008 · Cited by 21
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Kato, T., Casarini, I., Cobo, M., Finn, C. F., Hegi‐Johnson, F., Lü, S., Özgüroğlu, M., & Ramalingam, S. S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107414 · Cited by 21
Targeting targeted agents: open issues for clinical trial design
Bria, E., Maïo, M. D., Carlini, P., Cuppone, F., Giannarelli, D., Cognetti, F., & Milella, M. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-66 · Cited by 21
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes
Coate, L. E., & Shepherd, F. A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011399306 · Cited by 22
Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Couñago, F., Pérez, A. R., Calvo, P., Luna, J., Monroy, J. L., Taboada, B., Díaz, V. D., & de Dios, N. R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1512-2 · Cited by 21
The prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma
Zhu, G., Zhang, Y., Wang, Q., Che, S., Yang, Y., Chen, L., & Lin, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s195093 · Cited by 21
Hyperprogressive disease: a distinct effect of immunotherapy?
Popat, V., & Gerber, D. E. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.97 · Cited by 21
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects
Chuang, J. C., Neal, J. W., Niu, X., & Wakelee, H. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.016 · Cited by 20
Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer
Laine, A. M., Westover, K. D., & Choy, H. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.012 · Cited by 20
Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
Vale, C. L., Burdett, S., Fisher, D. J., Navani, N., Parmar, M., Copas, A. J., & Tierney, J. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.007 · Cited by 22
Risk of Fatal Pulmonary Events in Patients with Advanced Non-Small-Cell Lung Cancer Treated with EGF Receptor Tyrosine Kinase Inhibitors: A Comparative Meta-Analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Future Oncology · doi:10.2217/fon.15.16 · Cited by 20
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Kotsakis, A. P., & Georgoulias, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498581 · Cited by 20
The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
Stinchcombe, T. E. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0394-4 · Cited by 20
The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis
Qin, Q., Peng, B., & Li, B. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1621754 · Cited by 20
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
Limited, O. B. O. A. U., Patel, P. H., Alrifai, D., McDonald, F., & Forster, M. D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01071-5 · Cited by 20
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges
Mielgo-Rubio, X., Martín, M., Remón, J., Higuera, O., Calvo, V., Jarabo, J. R., Conde, E., Luna, J., Provencio, M., de Castro, J., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1255 · Cited by 20
Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?
Martínez, P., Martínez‐Martí, A., Navarro, A., Cedrés, S., & Felip, E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.018 · Cited by 20
Targeting EGFR and IGF 1R a promising combination therapy for metastatic cancer
Singh, I. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s369 · Cited by 20
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
Remón, J., Lévy, A., Gille, R., Martel‐Lafay, I., Bortolot, M., Hendriks, L. E. L., Finn, C. F., Leighl, N. B., Reck, M., & Pérol, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01080-4 · Cited by 19
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Remón, J., Lévy, A., Singh, P., Hendriks, L. E. L., Aldea, M. D., & Arrieta, O. G. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113268 · Cited by 19
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer
Xu, Y., Zhang, Y., & Ma, S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.017 · Cited by 19
Emerging Therapeutic Targets in Non-Small Cell Lung Cancer
Dy, G. K., & Adjei, A. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200808-099lc · Cited by 19
Personalized medicine for non-small-cell lung cancer
Mok, T. S. K., Zhou, Q. H., Leung, L. K. S., & Loong, H. H.-F. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.76 · Cited by 19
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
Dziadziuszko, R., & Jassem, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds351 · Cited by 20
Advanced EGFR Mutation-Positive Non–Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations
Kuykendall, A. T., & Chiappori, A. (2014) · Cancer Control · doi:10.1177/107327481402100110 · Cited by 20
Lung Cancer Outcomes in Women
Shafer, D. A., & Albain, K. S. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.10.001 · Cited by 19
Self-citation
L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.
Xia, W., Wang, J., Xu, Y., Jiang, F., & Xu, L. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.08.17 · Cited by 19
Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Price, K. A. R., Azzoli, C. G., & Gaspar, L. E. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.09.007 · Cited by 19
Self-citation
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Puri, S., Shafique, M. R., & Gray, J. E. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0556-7 · Cited by 18
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer
Cardenal, F., Arnaiz, M. D., Morán, T., Jové, J., Nadal, E., Porta, R., Solé, J. M., Brao, I., Palmero, R., Fuentes, R., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.021 · Cited by 18
Chemoradiotherapy of locally advanced nonsmall cell lung cancer
Antoni, D., & Mornex, F. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000265 · Cited by 18
Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision
Oh, I., & Ahn, S. (2017) · Radiation Oncology Journal · doi:10.3857/roj.2017.00108 · Cited by 18
Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review
Baldini, E., Tibaldi, C., & Paoli, C. D. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02326-6 · Cited by 18
Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas
Le, Q., & Raben, D. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.09.010 · Cited by 18
Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer
Bastos, B. R., Hatoum, G. F., Walker, G. R., Tolba, K. A., Takita, C., Gomez, J. E., Santos, E. S., Junior, G. L. L., & Raez, L. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce3e00 · Cited by 18
Treatment of Stage IIIA Non–Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist
Santana-Dávila, R., & Martins, R. G. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.013052 · Cited by 18
Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck
Juergens, R. A., Bratman, S. V., Tsao, M., Laurie, S. A., Kuruvilla, M. S., Razak, A. R. A., & Hansen, A. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.003 · Cited by 17
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Zarogoulidis, P., Tsirgogianni, K., Darwiche, K., Freitag, L., Tsavlis, D., Zissimopoulos, A., Zarogoulidis, P., Stratakos, G. K., Sarcav, T., Kovačević, T., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s91627 · Cited by 17
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Franco, A. O., Calvo, V., Franco, F., Provencio, M., & Califano, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-546 · Cited by 17
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
Melillo, G., Chand, V. K., Yovine, A. J., Gupta, A. K., & Massacesi, C. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01675-0 · Cited by 16
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
Engebraaten, O., Edvardsen, H., Løkkevik, E., Naume, B., Kristensen, V. N., Ottestad, L., & Natarajan, V. (2012) · ISRN Oncology · doi:10.5402/2012/176789 · Cited by 17
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni, L., Vavalà, T., & Novello, S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0429-x · Cited by 17
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non–Small-Cell Lung Cancer
Novello, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7587 · Cited by 17
EGFR pathway in advanced non-small cell lung cancer
Novello, S. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s168 · Cited by 16
Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
Berman, A. T., & Simone, C. B. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.11 · Cited by 16
Local Radiotherapy Intensification for Locally Advanced Non–small-cell Lung Cancer – A Call to Arms
Kalman, N. S., Weiss, E., Walker, P. R., & Rosenman, J. G. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.024 · Cited by 16
New developments in locally advanced nonsmall cell lung cancer
Huber, R. M., Kauffmann-Guerrero, D. E., Hoffmann, H., & Flentje, M. P. (2021) · European Respiratory Review · doi:10.1183/16000617.0227-2020 · Cited by 16
Radiotherapy of Non-Small-Cell Lung Cancer in the Era of EGFR Gene Mutations and EGF Receptor Tyrosine Kinase Inhibitors
Moschini, I., Dell’Anna, C., Losardo, P. L., Bordi, P., D’Abbiero, N., & Tiseo, M. (2015) · Future Oncology · doi:10.2217/fon.15.156 · Cited by 16
Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy
Komatsu, T., Kunieda, E., OIZUMI, Y., Tamai, Y., & Akiba, T. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.130 · Cited by 16
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes
Rajappa, S. J., Sharma, S., & Prasad, K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0876-4 · Cited by 16
Controversies in the management of stage III non-small-cell lung cancer
Biswas, T., Sharma, N., & Machtay, M. X. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.867809 · Cited by 15
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
Huber, R. M., Reck, M., & Thomas, M. (2013) · European Respiratory Journal · doi:10.1183/09031936.00143112 · Cited by 15
Anti-EGFR Agents: Current Status, Forecasts and Future Directions
Kwapiszewski, R., Pawlak, S., & Adamkiewicz, K. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0456-3 · Cited by 15
Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors
Lim, J. U. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.004 · Cited by 15
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients
Özçelik, M., Korkmaz, T., Odabaş, H., Gemici, C., Erçelep, Ö., Yuksel, S., Mert, A. G., Sürmeli, H., Işık, D., Aydın, D., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4776-1 · Cited by 15
Role of immunotherapy in stage III nonsmall cell lung cancer
Wrona, A. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000493 · Cited by 15
Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.
Bhardwaj, B., Revannasiddaiah, S., Bhardwaj, H., Balusu, S., & Shwaiki, A. (2016) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.10.35 · Cited by 14
Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer
Tantraworasin, A., Saeteng, Lertprasertsuke, Arreyakajohn, Kasemsarn, & Patumanond (2013) · Cancer Management and Research · doi:10.2147/cmar.s45642 · Cited by 14
Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy
Searle, E. J., Illidge, T., & Stratford, I. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.006 · Cited by 14
Adjuvant treatment of resected nonsmall cell lung cancer
Felip, E., Martínez‐Martí, A., Martínez, P., Cedrés, S., & Navarro, A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ca1b0 · Cited by 14
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai, S. H., Kim, C., & Veytsman, I. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0835-x · Cited by 14
Results of Trimodality Therapy in Patients With Stage IIIA (N2-Bulky) and Stage IIIB Non–Small-Cell Lung Cancer
Li, J., Dai, C.-H., Yu, L., Chen, P., Li, X., Shi, S.-B., & Wu, J.-R. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.048 · Cited by 14
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
Khurshid, H., DiPetrillo, T. A., Ng, T., Mantripragada, K. C., Birnbaum, A. E., Berz, D., Radie-Keane, K., Perez, K. J., Constantinou, M. A., Luppe, D., et al. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00056 · Cited by 14
Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Wang, Y., Wang, M., Wang, Q., Geng, Z., & Sun, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14707 · Cited by 15
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
Shafique, M. R., Robinson, L. A., & Antonia, S. J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s148009 · Cited by 14
Lenalidomide-Associated Tumor Flare Reaction Is Manageable in Patients With Chronic Lymphocytic Leukemia
Chanan-Khan, A. A., Whitworth, A., Bangia, N., Porter, C. W., & Lee, K. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2857 · Cited by 14
Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis
Liu, Y., Jiang, S., Lin, Y., Yu, H., Yu, L., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1066557 · Cited by 13
Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer
Zhuang, H., Zhao, L., Wang, P., Pang, Q., & Zhao, X. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s61977 · Cited by 13
Standard Treatment Option in Stage III Non–Small-Cell Lung Cancer: Case Against Trimodal Therapy and Consolidation Drug Therapy
Jeremic, B. M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.08.003 · Cited by 13
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
Reck, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.63 · Cited by 14
Treatment of Locally Advanced Non–Small Cell Lung Cancer
Tam, K. W., Daly, M. E., & Kelly, K. L. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.009 · Cited by 13
Self-citation
Radiothérapie et thérapies ciblées/immunothérapie
Antoni, D., Bockel, S., Deutsch, É., & Mornex, F. (2016) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2016.07.082 · Cited by 13
Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials
Wang, Q., Huang, H., Zeng, X., Ma, Y., Zhao, X., & Huang, M. (2016) · PeerJ · doi:10.7717/peerj.2550 · Cited by 14
Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: “MTD” or “ALARA”?
Ohri, N. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00205 · Cited by 13
Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
Hudson, A., Chan, C., Woolf, D., McWilliam, A., Hiley, C. T., O’Connor, J. P. B., Bayman, N., Blackhall, F. H., & Finn, C. F. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.006 · Cited by 13
Impact of hemostasis methods, electrocoagulation versus suture, in laparoscopic endometriotic cystectomy on the ovarian reserve: a randomized controlled trial.
Tanprasertkul, C., Ekarattanawong, S., Sreshthaputra, O., & Vutyavanich, T. (2014) · PubMed · Cited by 13
EGFR-directed therapies to treat non-small-cell lung cancer
Ho, C., & Laskin, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066772 · Cited by 13
Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells
Ikeda, R., Vermeulen, L. C., Lau, E., Jiang, Z., Kavanaugh, S. M., Yamada, K., & Kolesar, J. (2010) · Oncology Letters · doi:10.3892/ol.2010.198 · Cited by 13
Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer
Wakelee, H. A., & Chhatwani, L. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.09.001 · Cited by 13
Maintenance Treatment With Different Strategies in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Cai, H., Lin, Y., Li, W., & Li, X. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.010 · Cited by 12
Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
Liu, Y., Hao, X., Liu, D., Cheng, G., Zhang, S., Xiao, W., Hu, Y., Liu, J., He, M., Ding, C., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s240275 · Cited by 12
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
Lee, D.-S., Kim, Y., Kang, J. H., Lee, S., Kim, Y.-K., Ahn, M.-I., Han, D. H., Yoo, I.-R., Wang, Y.-P., Park, J.-G., et al. (2011) · Cancer Research and Treatment · doi:10.4143/crt.2011.43.1.32 · Cited by 12
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Looyenga, B. D., Cherni, I., MacKeigan, J. P., & Weiss, G. J. (2011) · Translational Oncology · doi:10.1593/tlo.10241 · Cited by 12
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study
Rubio, J. C., Fírvida-Pérez, J. L., Lázaro-Quintela, M., Barón-Duarte, F. J., Curbera, G. A.-J., Santomé, L., Afonso-Afonso, F. J., Amenedo, M., Huidobro, G., Campos, B., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2370-z · Cited by 12
Fractionated Scheme of Oral Vinorelbine as Single-Agent Therapy or in Combination With Cisplatin Concomitantly With Thoracic Radiotherapy in Stage III Non–Small-Cell Lung Cancer: Dose-Escalation Phase I Trial
Krzakowski, M. J., Lucas, C., & Gridelli, C. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.02.002 · Cited by 12
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
Ouwens, M., Darilay, A. T., Zhang, Y., Mukhopadhyay, P., Mann, H., Ryan, J., & Dennis, P. A. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100640 · Cited by 11
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study
Katayama, T., Matsuo, K., Kosaka, T., Sueda, T., Yatabe, Y., & Mitsudomi, T. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2010.07.002 · Cited by 11
What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review
Giaj‐Levra, N., Ricchetti, F., & Alongi, F. (2016) · Cancer Investigation · doi:10.3109/07357907.2015.1114121 · Cited by 11
Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting
Franco, P., Fiorentino, A., Dionisi, F., Fiore, M., Chiesa, S., Vagge, S., Cellini, F., Caravatta, L., Tombolini, M., Rose, F. D., et al. (2016) · Tumori Journal · doi:10.5301/tj.5000525 · Cited by 11
Personalized Treatment of Early-Stage Non-Small-Cell Lung Cancer: The Challenging Role of EGFR Inhibitors
Santarpía, M., Altavilla, G., Pitini, V. V., & Rosell, R. (2015) · Future Oncology · doi:10.2217/fon.14.320 · Cited by 11
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
Sangha, R. S., Lara, P. N., Mack, P. C., & Gandara, D. R. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283210489 · Cited by 11
Self-citation
Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer
Ishida, K., Hirose, T., Yokouchi, J., Oki, Y., Kusumoto, S., Sugiyama, T., Ishida, H., Shirai, T., Nakashima, M., Yamaoka, T., et al. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.252 · Cited by 11
Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
Zhang, C., Huang, C., Wang, J., Wang, X., & Li, K. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.002 · Cited by 11
Radiation Therapy for Thoracic Malignancies
Lee, V. H.-F., Li, Y., Jiang, Y. H., & Kong, F. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.09.007 · Cited by 11

Authors: Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R.
Affiliations: Sunnybrook Health Science Centre (CA)
ORCID: Kelly, Karen
Albain, Kathy S.
Ung, Yee C.
Gandara, David R.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2450-2456
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.4824
OpenAlex: W2153865661
Cited by: 573
References: 31
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 57 · 2012: 41
FWCI: 48.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Sanofi
National Institutes of Health (2u10ca038926-25, 5r01ca037663-18)
National Cancer Institute (CA35192, U10CA004919, CA 35176, CA-11083, CA52654, CA-45377, U10CA035261, CA35281, CA 74811, CA-35261, CA-46282, CA 20319, CA-32102, U10CA074647, CA 45450, CA35119, CA 42777, U10CA045377, CA04919, U10CA058882, U10CA074811, U10CA014028, U10CA045560, U10CA063848, U10CA035178, CA 74647, U10CA045808, CA35128, CA46368, CA46441, CA 63845, U10CA046368, CA45808, CA 45461, CA67575, U10CA035090, CA 14028, U10CA020319, U10CA086780, U10CA011083, CA-58882, CA35178, CA-45807, U10CA013612, CA 37663, U10CA035119, U10CA063850, CA35431, U10CA032102, U10CA046282, U10CA045461, U10CA052654, U10CA045450, U10CA042777, U10CA035281, CA 13612, U10CA063845, U10CA045807, U10CA063844, U10CA035431, CA-35262, U10CA035192, CA 38926, U10CA035262, CA63844, CA86780, U10CA035176, U10CA035128, CA-63850, CA-63848, CA45560, U10CA067575, CA-35090, U10CA046441)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, maintenance therapy, non-small cell lung cancer, stage III NSCLC, inoperable lung cancer, concurrent chemoradiotherapy, cisplatin, etoposide, thoracic radiotherapy, EGFR tyrosine kinase inhibitors, survival, toxic death
MeSH terms: Docetaxel, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Quinazolines, Remission Induction, Survival Rate, Maximum Tolerated Dose, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks